GANO KYLE (Chief Business Development Off) sold 0.2% of their position (300.00 shares) of NEUROCRINE BIOSCIENCES INC on the open market
Open‑market sale worth $42.6K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 11/4/2025ACC: 0001567160-25-000008
Officer· Chief Business Development Off
Since Aug 2018
-300.00
Net shares
Net seller
$42.6K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
613.00 acquired · 913.00 disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+613.00
Price / share
—
Trade value
—
% of position
0.4%
11/1/2025
140.11K→140.72K
Common Stock
Direct
Shares
−300.00
Price / share
$141.97
Trade value
$42.59K
% of position
0.2%
11/4/2025
140.71K→140.41K
Total
Net shares
+313.00
Net value
-$42.59K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/1/2025 | M · Option Exercise | +613.00 | — | — | 0.4% | 140.11K | 140.72K |
| Common Stock Direct | 11/4/2025 | S · Sale | −300.00 | $141.97 | $42.59K | 0.2% | 140.71K | 140.41K |
| Total | +313.00 | -$42.59K | ||||||
Derivative Transactions1
Restricted Stock Unit
Direct
Converts to
Common Stock
613.00 shares
Shares
−613.00
Strike price
Held after
1.84K
Exercisable
—
11/1/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Unit Direct | Common Stock613.00 shares | 11/1/2025 | M · Option Exercise | −613.00 | — | 1.84K |